New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to...
Scientific Research Achievements in Five Fields Showcase Hong Kong's Strength in Innovation and Technology Commercialisation HONG KONG, May 23, 2026 /PRNewswire/ -- The...
Showcasing Hong Kong's R&D Strength and Advancing Space Technology Applications HONG KONG, May 23, 2026 /PRNewswire/ -- The Hong Kong Applied Science and...
Click here for new content package including interviews, and b-roll footage Click here for images & VNR of Vivid Sydney 2026 Lights On launch moment...